Month: April 2022

VANCOUVER, British Columbia, April 29, 2022 (GLOBE NEWSWIRE) — Candelaria Mining Corp. (TSX-V: CAND, OTC PINK: CDELF) (the “Company”) announces that pursuant to the Company’s stock option plan and restricted share unit plan (together, the “Plans”), the Company granted today a total of 4,120,000 stock options (“Options”) and 461,677 restricted share units (“RSUs”) to directors, officers, employees and consultants of the Company. Each Option is exercisable into one common share of the Company for period of five years at an exercise price of $0.14 per share. All Options vest as follows: one-third after six months from the grant date, one-third at 12 months from the grant date and one-third at 18 months from the grant date. All RSU’s vest at one year from the grant date. All Options and RSUs are subject to the terms of the Company’s...

First novel, nonstimulant option for adults with ADHD in 20 years ADHD affects an estimated 10 million adults in the U.S.ROCKVILLE, Md., April 29, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) approved an expanded indication for Qelbree (viloxazine extended-release capsules) for the treatment of attention deficit hyperactivity disorder (ADHD) in adult patients aged 18 and older. The FDA has now approved Qelbree for the treatment of ADHD in children (starting at age 6), adolescents and adults. Approximately 16 million children, adolescents, and adults have ADHD in the U.S. While many children with ADHD outgrow...

Company to Host First Quarter 2022 Financial Results Conference Call on June 9 at 8:00 AM ET SHANGHAI, China, April 29, 2022 (GLOBE NEWSWIRE) — Bilibili Inc. (“Bilibili” or the “Company”) (NASDAQ: BILI and HKEX: 9626), an iconic brand and a leading video community for young generations in China, today announced that it has updated its net revenues guidance for the first quarter of 2022 and provided an update on the Company’s recent developments. With macro-economic disruption caused by the unexpected Covid-19 resurgence nationwide in China, and the increased Covid-19 restrictions and lockdowns in major cities including Shanghai since mid-March, the Company currently expects net revenues for the first quarter of 2022 to be in the range of RMB5.0 billion to RMB5.1 billion. This compares with the range of RMB5.3 billion to RMB5.5...

Not for distribution to U.S. news wire services or dissemination in the United States. Vancouver, British Columbia, April 29, 2022 (GLOBE NEWSWIRE) — St. James Gold Corp. (the “Company”) (TSXV: LORD) (OTCQB: LRDJF) (FSE: BVU3) is pleased to announce that, effective immediately, the Company has appointed Dr. Tsun Law to its Board of Directors. Dr. Tsun Law MD, MBA is a practicing Orthopedic Physician in South Florida, USA specializing in hip and knee osteoarthritis who is actively engaged in clinical research with a special focus on robotic and sensor technologies, medical innovation, and healthcare investments. Dr. Law has been published in numerous highly regarded peer reviewed medical journals and his research has been accepted for presentation at both national and international orthopedic surgery conferences. Dr. Law is working...

Toronto, ON, April 29, 2022 (GLOBE NEWSWIRE) — Canada Carbon Inc. (the “Company“) (TSX-V: CCB) (OTC: BRUZF) (Frankfurt: U7N1) is pleased to announce the appointment of Remantra Sheopaul as Chief Financial Officer of the Company, replacing Olga Nikitovic, effective immediately. The Company thanks Ms. Nikitovic for her tenure as Chief Financial Officer and Chief Executive Officer through December 2021 and for continuing in a consulting capacity, on accounting and financial matters, through April 2022. Mr. Sheopaul presently works with Marrelli Support Services which provides chief financial officer, accounting, regulatory, compliance and management advisory services to numerous issuers on the TSX, TSX Venture Exchange and other Canadian and U.S. exchanges. Mr. Sheopaul has a focus on building strong relationships with...

ORGOVYX® is the first and only oral androgen deprivation therapy for advanced hormone-sensitive prostate cancer in Europe Myovant expects to secure European commercialization partner ahead of anticipated launchesBASEL, Switzerland, April 29, 2022 (GLOBE NEWSWIRE) — Myovant Sciences (NYSE: MYOV) today announced that the European Commission (EC) has approved the marketing authorisation application for ORGOVYX® (relugolix, 120 mg) for the treatment of adult patients with advanced hormone-sensitive prostate cancer. The approval is applicable to all 27 European Union member states plus Iceland, Norway, and Liechtenstein. “Now for the first time, patients in Europe have the ability to rapidly reduce testosterone without hormonal flare in a convenient oral form,” said Juan Camilo Arjona Ferreira, Chief Medical Officer of Myovant Sciences,...

CARLSBAD, Calif, April 29, 2022 (GLOBE NEWSWIRE) — NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICESCompany reports strong revenue growth of 22% in Q4 and expects sequential increase in revenues for Q1 2022 – Management to host conference call on Monday, May 2, 2022 at 11:00 AM ET –Aurora Spine Corporation (“Aurora Spine” or the “Company”) (TSXV: ASG) (OTCQB: ASAPF), a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, today announced the financial results for the fourth quarter and fiscal year ended December 31, 2021. All figures are in U.S. dollars. Financial and Business Highlights21% Annual Sales Growth – The Company has experienced quarter over quarter sales growth each quarter in 2021 from $2.3 million in Q1 to approximately $3.0...

THIS NEWS RELEASE IS NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES MONTREAL, April 29, 2022 (GLOBE NEWSWIRE) — AM Resources Corporation (“AM” or the “Corporation”) (TSXV: AMR) (Frankfurt: 76A) is pleased to announce the closing of a second tranche of its previously announced non-brokered private placement (the “Offering”). Pursuant to the Offering, the Corporation raised aggregate gross proceeds of $446,000, consisting of the issuance of 8,920,000 units of the Corporation (each, a “Unit”) at a price of $0.05 per Unit. Each Unit is comprised of one common share of the Corporation and one half of one warrant. Each full warrant entitles the holder to acquire one common share of the Corporation at a price of $0.075 for a period of 24 months from the date of issuance. In connection with the...